Pablo R. Menéndez

The paper identifies a TET2-AGO2 regulatory axis that links epigenetic remodeling to myeloid commitment and leukemia progression.

The paper develops patient-derived AML PDX models that replicate primary AML biology and include subgroups lacking existing models, showing reduced leukemia growth after long-term chemotherapy.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

This study identifies that the costimulatory domain of CD19-CAR-T cells influences resistance development in B-cell malignancies by affecting CD19 loss and antigen escape.

This study integrates single-cell multi-omics data from CAR-T cells to identify factors influencing immunotherapy response in B-cell neoplasias.

This paper introduces an iCRISPRa system to activate transcription factors in iPSCs, identifying IGFBP2 as critical for hematopoietic progenitor production.

The paper introduces liCHi-C, a low-input Hi-C method, to map promoter-enhancer interactions in clinical samples and identify disease-relevant regulatory elements and structural variants.

The paper identifies IGFBP2 as a key factor secreted by arterial cells that enhances hematopoietic progenitor development in vitro.